(BW HealthWire) — IDEC Pharmaceuticals Corporation (Nasdaq:IDPH) today announced that Edward Rodriguez has been promoted to Vice President, Finance and Controller.
“Ed Rodriguez’s leadership, hard work and selfless commitment has been felt across all divisions for a number of years and has contributed to IDEC’s continuing success,” said Phil Schneider, Chief Financial Officer. “Of particular note has been his increasing responsibility and significant participation in IDEC’s last four equity or debt offerings.”
Within the Finance Department Mr. Rodriguez is responsible for risk management, tax planning, corporate taxation and lease financing. In addition, he is IDEC’s leader in managing compliance with the regulations and requirements for the Securities and Exchange Commission (SEC) and the Financial Accounting and Standards Board (FASB).
Mr. Rodriguez joined IDEC in 1991 as a Senior Manager, and was promoted to Director in 1996 and to Senior Director in 1999. Prior to joining IDEC, Mr. Rodriguez was a Senior Manager with KPMG LLP from 1984 until 1991. While at KPMG he obtained his Certified Public Accountant (CPA) license.
He graduated from San Diego State University with a Bachelor of Science degree in Business Administration in 1983. Mr. Rodriguez is a member of the Association of Bioscience Financial Officers, San Diego chapter, the American Institute of Certified Public Accountants, and the California Society of Certified Public Accountants.
IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases. IDEC’s antibody products act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic systems. For a menu of IDEC’s current news releases and quarterly reports or to retrieve a specific release, call 888/329-2309. On the Internet check the News Center at IDEC’s website: http://idecpharm.cdmail.biz.
The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from IDEC’s expectations. For example, the timing, success and cost of preclinical research and clinical studies, the timing, acceptability and review periods for regulatory filings, the timing of and ability to obtain regulatory approval of products, the achievement of future product sales, the level of manufacturing performance and the risk factors listed from time to time in IDEC’s SEC filings including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2000, may affect the actual results achieved by IDEC. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
IDEC Pharmaceuticals is a registered U.S. trademark of the company. The company’s headquarters is located at 3030 Callan Road, San Diego, CA 92121.
IDEC Pharmaceuticals’ press releases are available at no charge through Business Wire’s News on Demand Plus. For a menu of IDEC’s current press releases and quarterly reports or to retrieve a specific release, call 888/329-2309. On the Internet, check the News Center at IDEC’s website: http://idecpharm.cdmail.biz.
|IDEC Pharmaceuticals Corporation, San Diego